Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Oral Alpan

Allergy & Immunology Springfield, VA Medical Doctor

NPI 1881788610 CMS profile 130313

6212 Old Keene Mill Court, Springfield, VA 22152

Open in the dashboard

General payments

$87,767

509 records reported · program years 2019–2025

Research payments

$13,284

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$105,312 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Oral Alpan of Springfield, VA is reported in the CMS Open Payments database as having received $87,767 across 509 general payments and $13,284 in research payments paid to them. Separately, studies naming them as principal investigator received $105,312 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,173 104
2024 General $16,789 89
2023 General $14,657 67
2022 General $1,707 79
2022 Research $10,576 1
2021 General $703 32
2021 Research $2,708 2
2020 General $23,739 57
2019 General $27,001 81

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Oral Alpan
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Oral Alpan were reported at $3,173. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Oral Alpan Allergy & Immunology median Middle half National median
2019 $27,001 $594 $163–$1,512 $163
2020 $23,739 $426 $106–$1,233 $114
2021 $703 $638 $157–$1,708 $132
2022 $1,707 $790 $205–$1,961 $149
2023 $14,657 $852 $220–$2,147 $160
2024 $16,789 $865 $203–$2,267 $164
2025 $3,173 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pharming Healthcare, Inc. $28,968 60 payments
  2. Shire North American Group Inc $17,160 30 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $15,157 52 payments
  4. Genentech USA, Inc. $10,214 59 payments
  5. Becton, Dickinson and Company $8,783 4 payments
  6. AstraZeneca Pharmaceuticals LP $1,230 41 payments
  7. Genzyme Corporation $1,228 53 payments
  8. Regeneron Healthcare Solutions, Inc. $1,085 50 payments
  9. Pfizer Inc. $657 30 payments
  10. CSL Behring $616 18 payments
  11. Other $2,670 112 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,780 11 payments
  2. Consulting Fee $25,910 16 payments
  3. Food and Beverage $12,549 458 payments
  4. Honoraria $8,667 1 payment
  5. Travel and Lodging $4,791 18 payments
  6. Education $71 5 payments
Products named General payments · program years 2019–2025
  1. HYQVIA $30,896 25 payments
  2. JOENJA $28,104 24 payments
  3. Xolair $10,214 59 payments
  4. DUPIXENT Immunology $1,776 83 payments
  5. CUVITRU $1,061 40 payments
  6. DUPIXENT Inflammation And Immunology $1,007 47 payments
  7. RUCONEST $864 36 payments
  8. TEZSPIRE $649 19 payments
  9. Xembify $461 19 payments
  10. CUTAQUIG $407 21 payments
  11. Other $5,354 226 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. ADMA BioManufacturing LLC $13,284 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

535

Median for Allergy/ Immunology: 449

Drug cost

$1,023,605

Median for Allergy/ Immunology: $169,700

Branded share of claims

65.2%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 116 $566,898
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 42 $203,657
Cuvitru Immun Glob G(Igg)/Gly/Iga Ov50 Brand 19 $132,944
Xolair Omalizumab Brand 24 $85,153
Cromolyn Sodium Generic 19 $19,299
Breo Ellipta Fluticasone/Vilanterol Brand 11 $4,473
Epinephrine Generic 14 $3,223
Promethazine Hcl Generic 29 $2,645
Diphenhydramine Hcl Generic 47 $1,849
Sodium Chloride 0.9 % Sodium Chloride Brand 42 $1,193

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$394,837

Medicare's payments for the services billed

Medicare patients

209

Average age 71

Services billed

16,069

153 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 56%
Ischemic heart disease 22%
Depression 22%
Osteoporosis 22%
COPD 20%
Chronic kidney disease 18%
Diabetes 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JOENJA
  • Pharming Healthcare, Inc. $14,796
$14,796 — —
RUCONEST
  • Pharming Healthcare, Inc. $362
$362 — —
Xolair
  • Genentech USA, Inc. $244
$244 24 —
DUPIXENT
  • GENZYME CORPORATION $217
  • Regeneron Healthcare Solutions, Inc. $25
$242 — —
CUVITRU
  • Takeda Pharmaceuticals U.S.A., Inc. $180
$180 19 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

512 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record